Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | IGF1R | P08069 | 5/20 | 0.44 |
| ▸ | CDK4 | P11802 | 3/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.44 |
| ▸ | INSR | P06213 | 7/20 | 0.42 |
| ▸ | EGFR | P00533 | 6/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760525 | 0.87 | IGF1R (0.44) | CDK2IGF1RCDK4CCNE1INSR | |
| SCHEMBL3761151 | 0.84 | CDK2 (0.56) | CDK2IGF1RCDK4CCNE1INSR | |
| SCHEMBL3756701 | 0.83 | INSR (0.47) | IGF1RINSREGFRERBB2 | |
| SCHEMBL3762013 | 0.81 | CDK2 (0.62) | CDK2IGF1RCDK4CCNE1EGFR | |
| SCHEMBL3765209 | 0.81 | CDK2 (0.52) | CDK2IGF1RCDK4CCNE1INSR | |
| SCHEMBL3756635 | 0.80 | EGFR (0.53) | CDK2IGF1RCDK4CCNE1INSR | |
| SCHEMBL3762829 | 0.79 | IGF1R (0.44) | IGF1RINSREGFRERBB2 | |
| SCHEMBL3759789 | 0.77 | IGF1R (0.58) | IGF1RINSREGFRERBB2 | |
| SCHEMBL3759773 | 0.76 | IGF1R (0.63) | IGF1RINSREGFRERBB2TTK | |
| SCHEMBL3764899 | 0.76 | IGF1R (0.63) | CDK2IGF1RINSREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-2435435-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-01-29 | — | — | EP | disclosed |
| US-8536180-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138575-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | CDK2 2/4885IGF1R 1/4885CDK4 21/4885 |
| US-20100305118-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | CDK2 3/4885IGF1R 1/4885CDK4 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.